Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094571 | 0.85 | TAAR1 (0.46) | KDM4EALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL30618212 | 0.77 | ALDH1A1 (0.44) | PYCR1KDM4EALDH1A1KDM4AKDM5A | |
| SCHEMBL15012476 | 0.77 | ALDH1A1 (0.44) | PYCR1KDM4EALDH1A1KDM4AKDM5A | |
| SCHEMBL8516081 | 0.77 | ALDH1A1 (0.44) | PYCR1KDM4EALDH1A1KDM4AKDM5A | |
| SCHEMBL9730842 | 0.76 | ALDH1A1 (0.51) | ALDH1A1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL133171 | 0.76 | MAOB (0.45) | KDM4EALDH1A1TAAR1 | |
| SCHEMBL1145658 | 0.75 | KDM4E (0.51) | PYCR1KDM4EALDH1A1KDM4AKDM5A | |
| SCHEMBL10766986 | 0.74 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL1758623 | 0.74 | PYCR1 (0.44) | PYCR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL183627 | 0.74 | HRH3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1177168-A4 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA INC (US) | 2003-06-25 | — | — | EP | claimed |
| JP-2002541237-A | — | — | 2002-12-03 | — | — | JP | claimed |
| EP-1177168-A1 | CASPASE INHIBITORS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000061542-A1 | CASPASE INHIBITORS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2000-10-19 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1647551-B1 | OPTICALLY ACTIVE HALOHYDRIN DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE EPOXY ALCOHOL DERIVATIVE FROM THE SAME | KANEKA CORP (JP) | 2011-05-04 | — | — | EP | disclosed |
| US-7582781-B2 | epoxidation to produce 1,2-Epoxy-2-(2,4-difluorophenyl)butan-3-ol intermediate for pharmaceutical drugs, a triazole antifungal agent | KANEKA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-4898939-A | Process for preparing 2β-substituted-methylpenicillin derivatives | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1990-02-06 | — | — | US | disclosed |
| US-4891369-A | BETA-LACTAMASE INHIBITORS | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1990-01-02 | — | — | US | disclosed |
| EP-0331394-A1 | Process for preparing 2 beta-substituted-methylpenicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1989-09-06 | — | — | EP | disclosed |
| EP-0273599-A1 | Process for preparing 2beta-substituted-methyl-penicillin derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-07-06 | — | — | EP | disclosed |
| EP-0272016-A1 | 2beta-substituted-methylpenicillanic acid derivatives, and salts and esters thereof | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1988-06-22 | — | — | EP | disclosed |
| US-4539151-A | Benzothiazepine derivatives and their method of preparation | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4539150-A | HYPOTENSIVE AGENTS, SULFIDING, CYCLIZATION | MITSUI TOATSU CHEMICALS, INC. (JP) | 1985-09-03 | — | — | US | disclosed |
| US-4214094-A | ANTILIPEMIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | PYCR1 169/4885KDM4E 4578/4885ALDH1A1 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.